News & Insights

Cynata Therapeutics (CYP.ASX) is unlocking the potential of stem cells

Aug 05, 2021

MST Access Senior Research Analyst, Chris Kallos, CFA explores how Cynata Therapeutics (ASX:CYP) is unlocking the potential of stem cells in developing therapeutic products to treat serious disorders.

To read Chris Kallos, CFA's Initiation Report, please visit www.mstaccess.com.au.


Recent posts

All material on this website has been prepared by MST Financial Services Pty Limited (ABN 54 617 475 180, AFSL 500 557) for general informational purposes only and is not a solicitation of any offer to buy or sell any financial instrument or to participate in any trading strategy. Unless otherwise stated, the material presented on this site is not a research report as defined under ASIC guidance.

For wholesale clients only
This material is only prepared for wholesale clients pursuant to section 761G(7) of the Corporations Act (Commonwealth).

Please also refer to MST's Privacy Policy which can be viewed here. Terms of Use can be viewed here.

Contact Us
enquiries@mstfinancial.com.au
+612 8999 9988

MST Financial Head Office
Level 13, 14 Martin Place
Sydney NSW 2000

MST Melbourne Office
Level 2, 183-185 Flinders Lane
Melbourne VIC 3000